New small-molecule drug design strategies for fighting resistant influenza A

Acta Pharmaceutica Sinica B

Volumn 5, Issue 5, 2015, Pages 419-430

  Shen, Zuyuan ^a   Lou, Kaiyan ^a   Wang, Wei ^a,b  

^a EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b UNIVERSITY OF NEW MEXICO   (United States)

Author keywords

Drug discovery; Influenza A virus; M2 ion channel; Neuraminidase; Resistance

Indexed keywords

ALPINIA KATSUMADAIN EXTRACT; AMANTADINE; ANTIVIRUS AGENT; BENZBROMARONE; DICLAZURIL; FAVIPIRAVIR; HEMAGGLUTININ; LANINAMIVIR; NAPROXEN; NONSTRUCTURAL PROTEIN 1; NSC 89853; NUCLEOPROTEIN; OSELTAMIVIR; PERAMIVIR; PLANT EXTRACT; PROTEIN M2; RIBAVIRIN; RNA POLYMERASE; SIALIDASE; UNCLASSIFIED DRUG; ZANAMIVIR;

ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; DRUG BINDING SITE; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG EFFICACY; DRUG IDENTIFICATION; DRUG POTENCY; DRUG SCREENING; DRUG STRUCTURE; DRUG TARGETING; HUMAN; HYDROGEN BOND; IC50; INFLUENZA A; INFLUENZA A VIRUS; LIPOPHILICITY; NONHUMAN; PROTEIN PROTEIN INTERACTION; PROTEIN RNA BINDING; REVIEW; VIRUS REPLICATION; VIRUS TRANSMISSION;

EID: 84947201563     PISSN: 22113835     EISSN: 22113843     Source Type: Journal    
DOI: 10.1016/j.apsb.2015.07.006     Document Type: Review

References (119)

1. World Health Organization. Influenza (seasonal ) fact sheet N°211. 2014. Available from: . http://www.who.int/mediacentre/factsheets/fs211/en/.
2. Deyde VM, Xu XY, Bright RA, Shaw M, Smith CB, Zhang Y, et al. Surveillance of resistance to adamantanes among influenza A (H3N2) and A (H1N1) viruses isolated worldwide. J Infect Dis 2007, 196:249-257.
3. Moscona A. Oseltamivir resistance-disabling our influenza defenses. N Engl J Med 2005, 353:2633-2636.
4. Sheu TG, Fry AM, Garten RJ, Deyde VM, Shwe T, Bullion L, et al. Dual resistance to adamantanes and oseltamivir among seasonal influenza A(H1N1) viruses: 2008-2010. J Infect Dis 2011, 203:13-17.
5. Feng EG, Ye DJ, Li J, Zhang DY, Wang JF, Zhao F, et al. Recent advances in neuraminidase inhibitor development as anti-influenza drugs. ChemMedChem 2012, 7:1527-1536.
6. 2 proton channels of influenza A and B viruses. J Biol Chem 2006, 281:8997-9000.
7. Leonov H, Astrahan P, Krugliak M, Arkin IT. How do aminoadamantanes block the influenza M2 channel, and how does resistance develop?. J Am Chem Soc 2011, 133:9903-9911.
8. Furuse Y, Suzuki A, Oshitani H. Large-scale sequence analysis of M gene of influenza A viruses from different species: mechanisms for emergence and spread of amantadine resistance. Antimicrob Agents Chemother 2009, 53:4457-4463.
9. Krumbholz A, Schmidtke M, Bergmann S, Motzke S, Bauer K, Stech J, et al. High prevalence of amantadine resistance among circulating European porcine influenza A viruses. J Gen Virol 2009, 90:900-908.
10. 2 ion channel of influenza A virus. Proc Natl Acad Sci U S A 2013, 110:1315-1320.
11. Kolocouris N, Kolocouris A, Foscolos GB, Fytas G, Neyts J, Padalko E, et al. Synthesis and antiviral activity evaluation of some new aminoadamantane derivatives. 2. J Med Chem 1996, 39:3307-3318.
12. Stamatiou G, Kolocouris A, Kolocouris N, Fytas G, Foscolos GB, Neyts J, et al. Novel 3-(2-adamantyl)pyrrolidines with potent activity against influenza A virus-identification of aminoadamantane derivatives bearing two pharmacophoric amine groups. Bioorg Med Chem Lett 2001, 11:2137-2142.
13. Zoidis G, Fytas C, Papanastasiou I, Foscolos GB, Fytas G, Padalko E, et al. Heterocyclic rimantadine analogues with antiviral activity. Bioorg Med Chem 2006, 14:3341-3348.
14. Zarubaev VV, Golod EL, Anfimov PM, Shtro AA, Saraev VV, Gavrilov AS, et al. Synthesis and anti-viral activity of azolo-adamantanes against influenza A virus. Bioorg Med Chem 2010, 18:839-848.
15. 2 proton channel. J Am Chem Soc 2011, 133:13844-13847.
16. 2 proton channel. J Am Chem Soc 2014, 136:17987-17995.
17. Hu WH, Zeng SG, Li CF, Jie YL, Li ZY, Chen L. Identification of hits as matrix-2 protein inhibitors through the focused screening of a small primary amine library. J Med Chem 2010, 53:3831-3834.
18. 2 proton channels from solid-state NMR. Science 2010, 330:505-508.
19. Zhao X, Li CF, Zeng SG, Hu WH. Discovery of highly potent agents against influenza A virus. Eur J Med Chem 2011, 46:52-57.
20. 2 ion channel inhibitors. Antivir Res 2012, 96:91-99.
21. 2 ion channel of influenza A virus. Biochemistry 2009, 48:11872-11882.
22. 2 protein in saccharomyces cerevisiae: identification of a novel inhibitor of influenza virus. Antimicrob Agents Chemother 1995, 39:2204-2209.
23. 2 proton channel of influenza A virus. Nature 2008, 451:591-595.
24. Matrosovich MN, Matrosovich TY, Gray T, Roberts NA, Klenk H-D. Neuraminidase is important for the initiation of influenza virus infection in human airway epithelium. J Virol 2004, 78:12665-12667.
25. Suzuki T, Takahashi T, Guo CT, Hidari KI-PJ, Miyamoto D, Goto H, et al. Sialidase activity of influenza A virus in an endocytic pathway enhances viral replication. J Virol 2005, 79:11705-11715.
26. Yen HL, Hoffmann E, Taylor G, Scholtissek C, Monto AS, Webster RG, et al. Importance of neuraminidase active-site residues to the neuraminidase inhibitor resistance of influenza viruses. J Virol 2006, 80:8787-8795.
27. Von Itzstein M, Wu WY, Kok GB, Pegg MS, Dyason JC, Jin B, et al. Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature 1993, 363:418-423.
28. Davies BE. Pharmacokinetics of oseltamivir: an oral antiviral for the treatment and prophylaxis of influenza in diverse populations. J Antimicrob Chemother 2010, 65:II5-II10.
29. Kohno S, Kida H, Mizuguchi M, Hirotsu N, Ishida T, Kadota J, et al. Intravenous peramivir for treatment of influenza A and B virus infection in high-risk patients. Antimicrob Agents Chemother 2011, 55:2803-2812.
30. Koyama K, Takahashi M, Oitate M, Nakai N, Takakusa H, Miura S, et al. CS-8958, a prodrug of the novel neuraminidase inhibitor R-125489, demonstrates a favorable long-retention profile in the mouse respiratory tract. Antimicrob Agents Chemother 2009, 53:4845-4851.
31. Samson M, Pizzorno A, Abed Y, Boivin G. Influenza virus resistance to neuraminidase inhibitors. Antivir Res 2013, 98:174-185.
32. Pizzorno A, Bouhy X, Abed Y, Boivin G. Generation and characterization of recombinant pandemic influenza A (H1N1) viruses resistant to neuraminidase inhibitors. J Infect Dis 2011, 203:25-31.
33. Bloom JD, Gong LI, Baltimore D. Permissive secondary mutations enable the evolution of influenza oseltamivir resistance. Science 2010, 328:1272-1275.
34. Du J, Cross TA, Zhou HX. Recent progress in structure-based anti-influenza drug design. Drug Disc Today 2012, 17:1111-1120.
35. Collins PJ, Haire LF, Lin YP, Liu JF, Russell RJ, Walker PA, et al. Crystal structures of oseltamivir-resistant influenza virus neuraminidase mutants. Nature 2008, 453:1258-1261.
36. Russell RJ, Haire LF, Stevens DJ, Collins PJ, Lin YP, Blackburn GM, et al. The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design. Nature 2006, 443:45-49.
37. Rudrawar S, Dyason JC, Rameix-Welti M-A, Rose FJ, Kerry PS, Russell RJM, et al. Novel sialic acid derivatives lock open the 150-loop of an influenza A virus group-1 sialidase. Nat Commun 2010, 1:113.
38. Rudrawar S, Kerry PS, Rameix-Welti M-A, Maggioni A, Dyason JC, Rose FJ, et al. Synthesis and evaluation of novel 3-C-alkylated-Neu5Ac2en derivatives as probes of influenza virus sialidase 150-loop flexibility. Org Biomol Chem 2012, 10:8628-8639.
39. Wen WH, Wang SY, Tsai KC, Cheng YSE, Yang AS, Fang JM, et al. Analogs of zanamivir with modified C4-substituents as the inhibitors against the group-1 neuraminidases of influenza viruses. Bioorg Med Chem 2010, 18:4074-4084.
40. Xie YC, Xu DQ, Huang B, Ma XL, Qi WB, Shi FY, et al. Discovery of N-substituted oseltamivir derivatives as potent and selective inhibitors of H5N1 influenza neuraminidase. J Med Chem 2014, 57:8445-8458.
41. Amaro RE, Minh DDL, Cheng LS, Lindstrom WM, Olson AJ, Lin JH, et al. Remarkable loop flexibility in avian influenza N1 and its implications for antiviral drug design. J Am Chem Soc 2007, 129:7764-7765.
42. Kirchmair J, Rollinger JM, Liedl KR, Seidel N, Krumbholz A, Schmidtke M. Novel neuraminidase inhibitors: identification, biological evaluation and investigations of the binding mode. Future Med Chem 2011, 3:437-450.
43. An JH, Lee DCW, Law AHY, Yang CLH, Poon LLM, Lau ASY, et al. A novel small-molecule inhibitor of the avian influenza H5N1 virus determined through computational screening against the neuraminidase. J Med Chem 2009, 52:2667-2672.
44. Feng EG, Shin W-J, Zhu XL, Li J, Ye DJ, Wang J, et al. Structure-based design and synthesis of C-1- and C-4-modified analogs of zanamivir as neuraminidase inhibitors. J Med Chem 2013, 56:671-684.
45. Shie JJ, Fang JM, Wang SY, Tsai KC, Cheng YS, Yang AS, et al. Synthesis of tamiflu and its phosphonate congeners possessing potent anti-influenza activity. J Am Chem Soc 2007, 129:11892-11893.
46. Kim CU, Lew W, Williams MA, Wu HW, Zhang LJ, Chen XW, et al. Structure-activity relationship studies of novel carbocyclic influenza neuraminidase inhibitors. J Med Chem 1998, 41:2451-2460.
47. Mooney CA, Johnson SA, 't Hart P, Quarles Van Ufford L, De Haan CAM, Moret EE, et al. Oseltamivir analogues bearing N-substituted guanidines as potent neuraminidase inhibitors. J Med Chem 2014, 57:3154-3160.
48. Schade D, Kotthaus J, Riebling L, Kotthaus J, Müller-Fielitz H, Raasch W, et al. Development of novel potent orally bioavailable oseltamivir derivatives active against resistant influenza A. J Med Chem 2014, 57:759-769.
49. Grienke U, Schmidtke M, Kirchmair J, Pfarr K, Wutzler P, Dürrwald R, et al. Antiviral potential and molecular insight into neuraminidase inhibiting diarylheptanoids from Alpinia katsumadai. J Med Chem 2010, 53:778-786.
50. Rajasekaran D, Palombo EA, Yeo TC, Ley DLS, Tu CL, Malherbe F, et al. Identification of traditional medicinal plant extracts with novel anti-influenza activity. PLoS One 2013, 8:e79293.
51. Dao T-T, Tung B-T, Nguyen P-H, Thuong P-T, Yoo S-S, Kim E-H, et al. C-methylated flavonoids from Cleistocalyx operculatus and their inhibitory effects on novel influenza A (H1N1) neuraminidase. J Nat Prod 2010, 73:1636-1642.
52. Liu AL, Wang HD, Lee SM, Wang YT, Du GH. Structure-activity relationship of flavonoids as influenza virus neuraminidase inhibitors and their in vitro anti-viral activities. Bioorg Med Chem 2008, 16:7141-7147.
53. Dao TT, Nguyen PH, Lee HS, Kim E, Park J, Lim SI, et al. Chalcones as novel influenza A (H1N1) neuraminidase inhibitors from Glycyrrhiza inflata. Bioorg Med Chem Lett 2011, 21:294-298.
54. Hamilton BS, Whittaker GR, Daniel S. Influenza virus-mediated membrane fusion: determinants of hemagglutinin fusogenic activity and experimental approaches for assessing virus fusion. Viruses 2012, 4:1144-1168.
55. Terabayashi T, Morita M, Ueno M, Nakamura T, Urashima T. Inhibition of influenza-virus-induced cytopathy by sialylglycoconjugates. Carbohydr Res 2006, 341:2246-2253.
56. Job ER, Bottazzi B, Gilbertson B, Edenborough KM, Brown LE, Mantovani A, et al. Serum amyloid P is a sialylated glycoprotein inhibitor of influenza A viruses. PLoS One 2013, 8:e59623.
57. Hendricks GL, Weirich KL, Viswanathan K, Li J, Shriver ZH, Ashour J, et al. Sialylneolacto-N-tetraose c (LSTc)-bearing liposomal decoys capture influenza A virus. J Biol Chem 2013, 288:8061-8073.
58. Sun XL. Recent anti-influenza strategies in multivalent sialyloligosaccharides and sialylmimetics approaches. Curr Med Chem 2007, 14:2304-2313.
59. Gambaryan AS, Tuzikov AB, Chinarev AA, Juneja LR, Bovin NV, Matrosovich MN. Polymeric inhibitor of influenza virus attachment protects mice from experimental influenza infection. Antivir Res 2002, 55:201-205.
60. Bodian DL, Yamasaki RB, Buswell RL, Stearns JF, White JM, Kuntz ID. Inhibition of the fusion-inducing conformational change of influenza hemagglutinin by benzoquinones and hydroquinones. Biochemistry 1993, 32:2967-2978.
61. Antanasijevic A, Cheng H, Wardrop DJ, Rong LJ, Caffrey M. Inhibition of influenza H7 hemagglutinin-mediated entry. PLoS One 2013, 8:e76363.
62. Plotch SJ, OHara B, Morin J, Palant O, LaRocque J, Bloom JD, et al. Inhibition of influenza A virus replication by compounds interfering with the fusogenic function of the viral hemagglutinin. J Virol 1999, 73:140-151.
63. Yoshimoto J, Kakui M, Iwasaki H, Fujiwara T, Sugimoto H, Hattori N. Identification of a novel HA conformational change inhibitor of human influenza virus. Arch Virol 1999, 144:865-878.
64. Vanderlinden E, Göktas F, Cesur Z, Froeyen M, Reed ML, Russell CJ, et al. Novel inhibitors of influenza virus fusion: structure-activity relationship and interaction with the viral hemagglutinin. J Virol 2010, 84:4277-4288.
65. Luo G, Torri A, Harte WE, Danetz S, Cianci C, Tiley L, et al. Molecular mechanism underlying the action of a novel fusion inhibitor of influenza A virus. J Virol 1997, 71:4062-4070.
66. Leneva IA, Russell RJ, Boriskin YS, Hay AJ. Characteristics of arbidol-resistant mutants of influenza virus: implications for the mechanism of anti-influenza action of arbidol. Antivir Res 2009, 81:132-140.
67. Teissier E, Zandomeneghi G, Loquet A, Lavillette D, Lavergne J-P, Montserret R, et al. Mechanism of inhibition of enveloped virus membrane fusion by the antiviral drug arbidol. PLoS One 2011, 6:e15874.
68. Babar MM, Zaidi NU, Tahir M. Global geno-proteomic analysis reveals cross-continental sequence conservation and druggable sites among influenza virus polymerases. Antivir Res 2014, 112:120-131.
69. Furuta Y, Takahashi K, Shiraki K, Sakamoto K, Smee DF, Barnard DL, et al. T-705 (favipiravir) and related compounds: novel broad-spectrum inhibitors of RNA viral infections. Antivir Res 2009, 82:95-102.
70. Sidwell RW, Bailey KW, Wong MH, Barnard DL, Smee DF. In vitro and in vivo influenza virus-inhibitory effects of viramidine. Antivir Res 2005, 68:10-17.
71. Furuta Y, Gowen BB, Takahashi K, Shiraki K, Smee DF, Barnard DL. Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antivir Res 2013, 100:446-454.
72. Fodor E. The RNA polymerase of influenza A virus: mechanisms of viral transcription and replication. Acta Virol 2013, 57:113-122.
73. Lv HM, Guo XL, Gu RX, Wei DQ. Free energy calculations and binding analysis of two potential anti-influenza drugs with polymerase basic protein-2 (PB2). Protein Peptide Lett 2011, 18:1002-1009.
74. Dias A, Bouvier D, Crépin T, McCarthy AA, Hart DJ, Baudin F, et al. The cap-snatching endonuclease of influenza virus polymerase resides in the PA subunit. Nature 2009, 458:914-918.
75. N reveals an endonuclease active site. Nature 2009, 458:909-913.
76. Tomassini J, Selnick H, Davies ME, Armstrong ME, Baldwin J, Bourgeois M, et al. Inhibition of cap (m-7GpppXm)-dependent endonuclease of influenza virus by 4-substituted 2, 4-dioxobutanoic acid compounds. Antimicrob Agents Chemother 1994, 38:2827-2837.
77. Tomassini JE, Davies ME, Hastings JC, Lingham R, Mojena M, Raghoobar SL, et al. A novel antiviral agent which inhibits the endonuclease of influenza viruses. Antimicrob Agents Chemother 1996, 40:1189-1193.
78. Parkes KEB, Ermert P, Fässler J, Ives J, Martin JA, Merrett JH, et al. Use of a pharmacophore model to discover a new class of influenza endonuclease inhibitors. J Med Chem 2003, 46:1153-1164.
79. DuBois RM, Slavish PJ, Baughman BM, Yun MK, Bao J, Webby RJ, et al. Structural and biochemical basis for development of influenza virus inhibitors targeting the PA endonuclease. PLoS Pathog 2012, 8:e1002830.
80. Kowalinski E, Zubieta C, Wolkerstorfer A, Szolar OHJ, Ruigrok RWH, Cusack S. Structural analysis of specific metal chelating inhibitor binding to the endonuclease domain of influenza pH1N1 (2009) polymerase. PLoS Pathog 2012, 8:e1002831.
81. Palu G, Loregian A. Inhibition of herpesvirus and influenza virus replication by blocking polymerase subunit interactions. Antivir Res 2013, 99:318-327.
82. N complex from an avian influenza H5N1 virus. Nature 2008, 454:1123-1126.
83. Obayashi E, Yoshida H, Kawai F, Shibayama N, Kawaguchi A, Nagata K, et al. The structural basis for an essential subunit interaction in influenza virus RNA polymerase. Nature 2008, 454:1127-1131.
84. Muratore G, Goracci L, Mercorelli B, Foeglein A, Digard P, Cruciani G, et al. Small molecule inhibitors of influenza A and B viruses that act by disrupting subunit interactions of the viral polymerase. Proc Natl Acad Sci U S A 2012, 109:6247-6252.
85. Massari S, Nannetti G, Goracci L, Sancineto L, Muratore G, Sabatini S, et al. Structural investigation of cycloheptathiophene-3-carboxamide derivatives targeting influenza virus polymerase assembly. J Med Chem 2013, 56:10118-10131.
86. Lepri S, Nannetti G, Muratore G, Cruciani G, Ruzziconi R, Mercorelli B, et al. Optimization of small-molecule inhibitors of influenza virus polymerase: from thiophene-3-carboxamide to polyamido scaffolds. J Med Chem 2014, 57:4337-4350.
87. Loregian A, Coen DM. Selective anti-cytomegalovirus compounds discovered by screening for inhibitors of subunit interactions of the viral polymerase. Chem Biol 2006, 13:191-200.
88. Muratore G, Mercorelli B, Goracci L, Cruciani G, Digard P, Palu G, et al. Human cytomegalovirus inhibitor AL18 also possesses activity against influenza A and B viruses. Antimicrob Agents Chemother 2012, 56:6009-6013.
89. Fukuoka M, Minakuchi M, Kawaguchi A, Nagata K, Kamatari YO, Kuwata K. Structure-based discovery of anti-influenza virus A compounds among medicines. Biochim Biophys Acta - Gen Subj 2012, 1820:90-95.
90. Sugiyama K, Obayashi E, Kawaguchi A, Suzuki Y, Tame JRH, Nagata K, et al. Structural insight into the essential PB1-PB2 subunit contact of the influenza virus RNA polymerase. EMBO J 2009, 28:1803-1811.
91. Chase G, Wunderlich K, Reuther P, Schwemmle M. Identification of influenza virus inhibitors which disrupt of viral polymerase protein-protein interactions. Methods 2011, 55:188-191.
92. Li CF, Ba Q, Wu AP, Zhang H, Deng T, Jiang TJ. A peptide derived from the C-terminus of PB1 inhibits influenza virus replication by interfering with viral polymerase assembly. FEBS J 2013, 280:1139-1149.
93. Portela A, Digard P. The influenza virus nucleoprotein: a multifunctional RNA-binding protein pivotal to virus replication. J Gen Virol 2002, 83:723-734.
94. Amorim M-J, Read EK, Dalton RM, Medcalf L, Digard P. Nuclear export of influenza A virus mRNAs requires ongoing RNA polymerase II activity. Traffic 2007, 8:1-11.
95. Kukol A, Hughes DJ. Large-scale analysis of influenza A virus nucleoprotein sequence conservation reveals potential drug-target sites. Virology 2014, 454-455:40-47.
96. Lejal N, Tarus B, Bouguyon E, Chenavas S, Bertho N, Delmas B, et al. Structure-based discovery of the novel antiviral properties of naproxen against the nucleoprotein of influenza A virus. Antimicrob Agents Chemother 2013, 57:2231-2242.
97. Kao RY, Yang D, Lau L-S, Tsui WH, Hu LH, Dai J, et al. Identification of influenza A nucleoprotein as an antiviral target. Nat Biotechnol 2010, 28:600-605.
98. Gerritz SW, Cianci C, Kim S, Pearce BC, Deminie C, Discotto L, et al. Inhibition of influenza virus replication via small molecules that induce the formation of higher-order nucleoprotein oligomers. Proc Natl Acad Sci U S A 2011, 108:15366-15371.
99. Cheng HM, Wan JT, Lin M-I, Liu YX, Lu XY, Liu JS, et al. Design, synthesis, and in vitro biological evaluation of 1H-1,2,3-triazole-4-carboxamide derivatives as new anti-influenza a agents targeting virus nucleoprotein. J Med Chem 2012, 55:2144-2153.
100. Su C-Y, Cheng T-JR, Lin M-I, Wang SY, Huang W-I, Lin-Chu S-Y, et al. High-throughput identification of compounds targeting influenza RNA-dependent RNA polymerase activity. Proc Natl Acad Sci U S A 2010, 107:19151-19156.
101. Amorim MJ, Kao RY, Digard P. Nucleozin targets cytoplasmic trafficking of viral ribonucleoprotein-rab11 complexes in influenza A virus infection. J Virol 2013, 87:4694-4703.
102. Ayllon J, García-Sastre A. The NS1 protein: a multitasking virulence factor 2015, 73-107. Springer International Publishing, Switzerland. M.B.A. Oldstone, R.W. Compans (Eds.).
103. Ayllon J, Hale BG, García-Sastre A. Strain-specific contribution of NS1-activated phosphoinositide 3-kinase signaling to influenza A virus replication and virulence. J Virol 2012, 86:5366-5370.
104. Marc D, Barbachou S, Soubieux D. The RNA-binding domain of influenzavirus non-structural protein-1 cooperatively binds to virus-specific RNA sequences in a structure-dependent manner. Nucl Acids Res 2013, 41:434-449.
105. Das K, Ma L-C, Xiao R, Radvansky B, Aramini J, Zhao L, et al. Structural basis for suppression of a host antiviral response by influenza A virus. Proc Natl Acad Sci U S A 2008, 105:13093-13098.
106. Gack MU, Albrecht RA, Urano T, Inn K-S, Huang I-C, Carnero E, et al. Influenza A virus NS1 targets the ubiquitin ligase TRIM25 to evade recognition by the host viral RNA sensor RIG-I. Cell Host Microbe 2009, 5:439-449.
107. Hale BG, Kerry PS, Jackson D, Precious BL, Gray A, Killip MJ, et al. Structural insights into phosphoinositide 3-kinase activation by the influenza A virus NS1 protein. Proc Natl Acad Sci U S A 2010, 107:1954-1959.
108. Engel DA. The influenza virus NS1 protein as a therapeutic target. Antivir Res 2013, 99:409-416.
109. Basu D, Walkiewicz MP, Frieman M, Baric RS, Auble DT, Engel DA. Novel influenza virus NS1 antagonists block replication and restore innate immune function. J Virol 2009, 83:1881-1891.
110. Ai HX, Zhang L, Chang AK, Wei HY, Che YC, Liu HS. Virtual screening of potential inhibitors from TCM for the CPSF30 binding site on the NS1A protein of influenza A virus. J Mol Model 2014, 20:2142.
111. Walkiewicz MP, Basu D, Jablonski JJ, Geysen HM, Engel DA. Novel inhibitor of influenza non-structural protein 1 blocks multi-cycle replication in an RNase L-dependent manner. J Gen Virol 2011, 92:60-70.
112. Ai HX, Zheng FL, Zhu CY, Sun TT, Zhang L, Liu X, et al. Discovery of novel influenza inhibitors targeting the interaction of dsRNA with the NS1 protein by structure-based virtual screening. Int J Bioinform Res Appl 2010, 6:449-460.
113. Cho EJ, Xia SL, Ma LC, Robertus J, Krug RM, Anslyn EV, et al. Identification of influenza virus inhibitors targeting NS1A utilizing fluorescence polarization-based high-throughput assay. J Biomol Screen 2012, 17:448-459.
114. Maroto M, Fernandez Y, Ortin J, Pelaez F, Cabello MA. Development of an HTS assay for the search of anti-influenza agents targeting the interaction of viral RNA with the NS1 protein. J Biomol Screen 2008, 13:581-590.
115. Dunning J, Baillie JK, Cao B, Hayden FG International Severe Acute Respiratory and Emerging Infection Consortium. Antiviral combinations for severe influenza. Lancet Infect Dis 2014, 14:1259-1270.
116. Ilyushina NA, Hoffmann E, Salomon R, Webster RG, Govorkova EA. Amantadine-oseltamivir combination therapy for H5N1 influenza virus infection in mice. Antivir Ther 2007, 12:363-370.
117. Smee DF, Hurst BL, Wong M-H, Bailey KW, Tarbet EB, Morrey JD, et al. Effects of the combination of favipiravir (T-705) and oseltamivir on influenza A virus infections in mice. Antimicrob Agents Chemother 2010, 54:126-133.
118. Kim W-Y, Suh GY, Huh JW, Kim S-H, Kim M, Kim YS, et al. Triple-combination antiviral drug for pandemic H1N1 influenza virus infection in critically ill patients on mechanical ventilation. Antimicrob Agents Chemother 2011, 55:5703-5709.
119. Seo S, Englund JA, Nguyen JT, Pukrittayakamee S, Lindegardh N, Tarning J, et al. Combination therapy with amantadine, oseltamivir and ribavirin for influenza A infection: safety and pharmacokinetics. Antivir Ther 2013, 18:377-386.